Dr. Deborah Birx and Victoria Wang join Nanolive SA’s Board of Directors

Tolochenaz, Vaud, Switzerland — September 20th, 2022 - Nanolive SA, a leading live cell imaging and analysis company, announces today two important new additions to its board of directors.

After the successful closing of a US $22.2 million Series C equity financing, Nanolive announces the appointment of two extraordinary women to its board of directors: Dr. Deborah Birx and Mrs. Victoria Wang.

Dr. Deborah Birx is an American physician, scientist, and diplomat. Dr Birx served as the Director of the Division of Retroviral Research in DoD from 1995-2005, Director of Centers for Disease Control and Prevention’s Division of Global HIV/AIDS (DGHA) from 2005 to 2014, Director of the U.S. response to HIV/AIDS overseeing $6 billion investment annually 2014-2021, U.S. lead board member to the Global Fund 2014-2021, and served the United States as the White House Coronavirus Response Coordinator from 2020 to 2021.

“It has been an honor to integrate and translate cutting edge technology to change the course of pandemics across the globe. Trained as a laboratory and clinical cellular immunologist I am excited to join the board of Nanolive SA, bringing my translational medicine and data driven expertise to this exciting technology. Nanolive innovation is critical to next generation cancer therapy, understanding the immune disruptions of long COVID, and ensuring a deeper understanding of host and pathogen interactions.”

Dr. Deborah Birx

Mrs. Victoria Wang

Mrs. Victoria Wang is a Taiwanese American investment principal at Taiwania Capital with extensive experience in managing biotech investments and cultivating innovative technology in the life science and medical device industries. Having trained in innovation management and public health, Mrs. Wang focuses on discovering deep technology closer to environmental
sustainability, making life science and medicine more inclusive to allow scientists and physicians to exploit rich biological information for impactful epidemiological data analysis.

“I have grown accustomed to discovering cutting-edge technologies and extraordinary talents in Switzerland from my past decades of experience as a senior executive of a Swiss/American life science company. Nanolive’s label-free live cell imaging technology and dynamic analysis solutions are revolutionizing cell biology which will accelerate drug discovery process and make cell-based therapies more quantifiable. I am very honored to be part of the board connecting Nanolive to many parts of the world.”

The investment round was led by an affiliate of Innoviva, a US-based NASDAQ-listed life science company, and Taiwania Capital, a leading life science venture capital company based in Taiwan and active in San Francisco and Boston.

Nanolive’s cutting edge state-of-the-art label-free live cell digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.

Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provide researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.

“Nanolive’s next generation product lineup is more ambitious than ever - and our board is key” says Dr. Yann Cotte, Nanolive’s CEO and Co-Founder. “We are extremely honored to welcome two outstanding women to Nanolive’s board. Victoria’s and Deborah’s deep knowledge in innovation-driven biotech and infectious diseases and health is a massive step towards fulfilling Nanolive’s mission to fundamentally transform the discovery and development of therapeutics.

ABOUT NANOLIVE SA

Nanolive SA is a Swiss company pioneer in the development and commercialization of innovative label-free, non-invasive live cell imaging and state-of-the-art digital analytical solutions. Nanolive’s breakthrough live cell imaging and analysis platforms accelerate innovation in growth industries such as drug discovery and cell therapy. The Swiss company’s groundbreaking solutions combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights to longstanding questions in medicine such as the mechanisms involved in cancer and neurodegenerative diseases.

Find more information at [www.nanolive.ch](http://www.nanolive.ch) and follow the company on [LinkedIn](https://www.linkedin.com).
ABOUT INNOVIVA INC.

Innoviva is a diversified holding company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (GSK), as well as a growing portfolio of innovative healthcare investments and assets in areas of significant unmet medical need.

ABOUT TAIWANIA CAPITAL

Taiwania Capital is a leading venture capital company in Taiwan with investments in both life science and ICT industries. With funds designated for life science and bio-converging technologies, Taiwania focuses on investing in early to late-stage firms with a mission to build collaboration between Taiwan and worldwide partners by leveraging expertise of Taiwan’s vibrant biotech ecosystems, and exceptional healthcare services.

Locust Walk, a leading life sciences transaction advisory firm, served as transaction advisor to Nanolive SA.

For Media Inquiries:

Nanolive SA
Route de Lully, 5B
1131 Tolochenaz
Switzerland
lookinginsidelife@nanolive.ch